Posted on 10 October 2014
esprimed SAS has announced the H1 2015 market release of services developed in partnership with CEA LIST. The company, which specializes in medical physics for imaging, will now offer patients a personalized dose calculation technology. At the same time, esprimed is forming a scientific advisory board tasked with providing an independent review of the company’s activities.
Interventional radiology and new minimally-invasive surgery techniques are increasing caregiver and patient radiation exposure times and augmenting the doses received. Since 2012 esprimed has been conducting R&D with CEA LIST focused on the control of radiation protection of caregivers and patients.
Today, esprimed is entering a crucial phase in its technological and clinical R&D. “We plan to complete new calculation tools by year’s end. These tools will position us to offer personalized services that respond to practitioners’ concerns, that improve patient care, and that reduce doses as much as possible,” said esprimed CEO Jérémy Coulot. The new technology generates results backed by analysis and recommendations.
The company has hired new staff, invested in its in-house research resources, and has set up partnerships with top-tier clinical researchers at the Caen University Medical Center and the Henri Mondor University Medical Center in the greater Paris area to validate lab results in clinical conditions and get feedback from practitioners. The goal is for esprimed to release its new services in the first half of 2015.
esprimed also announced that it is forming a scientific advisory board to provide an objective review of the company’s R&D activities. “esprimed is committed to strong values like excellence in service, high-level know-how, and attention to detail. We have built close relationships with our customers. As our company moves forward, we are more committed than ever to maintaining the same level of quality. Our multidisciplinary scientific advisory board, made up of leaders from medicine and science, will help us confirm that our R&D strategies are the right ones and get expert opinions on the services we offer,” said Coulot.
The first meeting of the new scientific advisory board will be held by the end of 2014; esprimed will announce the board’s members on the company’s new website, slated to go online in the coming weeks.
And esprimed’s employees will be on hand at radiology trade fair Journées Françaises de Radiologie diagnostique et interventionnelle to be held from October 16 to 20 in Paris. The company will present its new services and R&D in the field of radiology risk management at a booth in the interventional radiology section of the fair.
esprimed offers scientific consulting and services to medical imaging centers to help them manage radiology risk and quality more effectively. The company provides services in quality control, training, dose optimization, radioprotection, and clinical researching in the field of medical imaging. Founded in 2009, esprimed is a spinoff of the Gustave Roussy Cancer Institute in Villejuif, near Paris. The company is located at Villejuif Bio Park and is backed by Cancer Campus and the Val de Marne Chamber of Commerce and Industry.
The French Alternative Energies and Atomic Energy Commission (CEA) is a government research institute operating in four major fields: low-carbon energy, information and healthcare technologies, very large research infrastructures, and global security and defense. The institute conducts international-caliber basic research and has earned recognition for its capacity to develop broad, deep knowledge of the fields in which it operates. The CEA runs joint research and development programs with partners from academia and industry. With 16,000 research scientists and staff, the CEA is a major European research organization and is playing an increasing role in the global research arena.
CEA LIST is a CEA Tech institute reporting to the CEA Technology Research Division and specializing in smart digital systems. CEA LIST R&D programs focus on topics with the capacity to help transform the economy and society, from advanced manufacturing and embedded systems to ambient intelligence and controlling ionizing radiation for healthcare. CEA LIST develops advanced technology and runs tech transfer programs to ensure that its industrial partners can remain competitive on global markets. CEA LIST earned the prestigious Institut Carnot label in 2006, a mark of quality in industrial research partnerships.